Trump nominates Heidi Overton to lead FDA as GLP-1 and peptide compounding decisions wait
Overton would inherit two unresolved compounding decisions — the 503A peptide bulks list and a proposed 503B exclusion for GLP-1s — while the FDA's ban on bulk GLP-1 compounding stands.
President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to lead the FDA on Aug. 19, 2026, his third choice for the post [1]. She has made no public statements on peptide compounding, the 503A or 503B bulks lists, or GLP-1 policy, and no Senate hearing date has been set [1].
According to a regulatory timeline tracking the nomination, acting commissioner Kyle Diamantas and former Rep. Brad Wenstrup (R-Ohio) both declined the job before Overton was chosen [1]. Senate Health, Education, Labor and Pensions Committee chair Bill Cassidy has called her record "alone is almost disqualifying" [1].
Two compounding dockets would land on the next commissioner's desk, confirmed or acting: the 503A bulks-list rulemaking (docket FDA-2018-N-4845) and an undecided 503B exclusion for GLP-1 drugs [1]. The 503A process follows a July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee, which recommended six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — for the 503A Bulks List and did not recommend emideltide (DSIP) [1]. That vote is advisory and nonbinding, no proposed rule has been published, formal rulemaking can take up to a year, and none of the six is lawfully compoundable today [1].
The GLP-1 track is separate. A proposal published April 30, 2026 would exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, and it remains undecided [1]. On Aug. 27, 2026, the Fifth Circuit upheld the FDA's removal of Ozempic, Wegovy, Mounjaro and Zepbound from the drug shortage list, ending bulk 503B compounding of these molecules for general use; patient-specific 503A compounding for an individual with a documented medical need remains lawful [1].
Also on Aug. 19, Novo Nordisk formally asked the FDA to place semaglutide on the Demonstrable Difficulties for Compounding lists, a request first filed in October 2024 under docket FDA-2017-N-2562, joining Eli Lilly's push to bar GLP-1 compounding [1]. In a parallel enforcement track, the FDA's Center for Drug Evaluation and Research issued warning letters on Aug. 24, 2026 to five online sellers — Peptide Partners LLC, Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC and TXP Innovations LLC — over injectable semaglutide, tirzepatide, retatrutide, tesamorelin, elamipretide and bremelanotide sold as unapproved new drugs; the letters were posted Sept. 1 [1].
Why it matters for patients
The practical rules for compounded GLP-1s are not in question right now: bulk compounding of semaglutide and tirzepatide for general use is no longer allowed after the Fifth Circuit ruling, while patient-specific compounding for a documented medical need remains lawful [1]. What is unresolved is how the agency will police that line, and the 503B exclusion proposal that would keep the restriction in place even during a future shortage is still pending [1].
For people who take compounded peptides, nothing has changed: the six peptides a federal advisory panel recommended in July are not on the 503A Bulks List and are not lawfully compoundable today [1]. Peptides still flagged by the FDA as potentially presenting significant safety risks as of the agency's April 22, 2026 list are GHRP-2, GHRP-6, ipamorelin acetate (503B) and kisspeptin-10 (503A) [1].
Because Overton has not spoken publicly on any of these questions, where she would take the agency has not been reported [1]. The nomination itself is also not final: no hearing has been scheduled [1].
What happens next
No Senate confirmation hearing date has been set for Overton [1]. The FDA has not set a timeline for a proposed or final 503A Bulks List rule, so the six recommended peptides remain not lawfully compoundable in the meantime [1]. The April 30 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list remains undecided [1]. The five sellers that received August warning letters face 15-business-day response windows, with possible escalation to seizure and injunction [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.